G1 Therapeutics - GTHX Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.

6 brokers have issued 12 month price objectives for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they predict the company's stock price to reach $16.60 in the next year. This suggests a possible upside of 545.9% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.

G1 Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, GTHX shares have decreased by 52.7% and is now trading at $2.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our GTHX earnings forecast.

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.12. The firm had revenue of $10.25 million for the quarter, compared to analyst estimates of $9.61 million. G1 Therapeutics had a negative net margin of 287.63% and a negative trailing twelve-month return on equity of 209.92%.

Invesco Nasdaq Future Gen 200 ETF holds 4,161 shares of GTHX stock, representing 0.28% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (6.55%), JPMorgan Chase & Co. (4.74%), Millennium Management LLC (3.90%), Marshall Wace LLP (2.32%), Renaissance Technologies LLC (1.51%) and Raymond James & Associates (1.16%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends.

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GTHX stock can currently be purchased for approximately $2.57.

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $132.77 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

The company employs 148 workers across the globe.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.